About the IOV-END-201 trial
IOV-END-201 is evaluating whether lifileucel, an investigational TIL cell therapy, can be a new way to fight against advanced endometrial cancer that progressed after prior treatment.
The trial is recruiting patients in the U.S. to determine whether lifileucel is safe and can:
- Reduce tumor size
- Slow tumor progression (growth)
- Eliminate tumors that show up on scans
- Prevent the cancer from worsening
Patients may be eligible to participate in this trial if they:
- Are 18 years of age or older
- Have endometrial cancer that is unresectable (cannot be removed with surgery) or metastatic (has spread to a different part of the body)
- Have received prior chemotherapy and immunotherapy
- Have at least 1 tumor that cannot be removed and 1 tumor that can be tracked on scans
Here is what patients can expect in the trial
Patients will undergo screening to see if they can participate in the trial. If they qualify, they will:
- Receive lifileucel treatment
- Be monitored by a special team to check if the treatment is working well
Find a trial location
The trial is currently recruiting patients at the following locations:
The list of trial locations will be updated as more sites become available. Check back if you do not yet see a convenient trial site. You can also contact a trial site to ask about travel support that may be offered.
Get started
This website is intended for a U.S. audience. TIL cell therapy is not yet approved by any regulatory or health agency for the investigational uses described in this website. This website is for educational purposes only and is not intended to replace discussions with a healthcare professional.
